Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up (2014)
- Authors:
- USP affiliated authors: HALLAK, JAIME EDUARDO CECILIO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; QUEIROZ, REGINA HELENA COSTA - FCFRP
- Unidades: FMRP; FCFRP
- DOI: 10.1177/2045125313507738
- Subjects: ANTIPSICÓTICOS (EFEITOS ADVERSOS); GANHO DE PESO; ANTROPOMETRIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Therapeutic Advances in Psychopharmacology
- ISSN: 2045-1253
- Volume/Número/Paginação/Ano: v. 4, n. 1, p. 30-36, 2014
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
BALBÃO, Marina Salviato et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology, v. 4, n. 1, p. 30-36, 2014Tradução . . Disponível em: https://doi.org/10.1177/2045125313507738. Acesso em: 24 abr. 2024. -
APA
Balbão, M. S., Hallak, J. E. C., Nunes, E. A., Mello, M. H. de, Triffoni-Melo, A. de T., Ferreira, F. I. de S., et al. (2014). Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology, 4( 1), 30-36. doi:10.1177/2045125313507738 -
NLM
Balbão MS, Hallak JEC, Nunes EA, Mello MH de, Triffoni-Melo A de T, Ferreira FI de S, Chaves C, Durão AMS, Ramos APP, Crippa JA de S, Queiroz RHC. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up [Internet]. Therapeutic Advances in Psychopharmacology. 2014 ; 4( 1): 30-36.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1177/2045125313507738 -
Vancouver
Balbão MS, Hallak JEC, Nunes EA, Mello MH de, Triffoni-Melo A de T, Ferreira FI de S, Chaves C, Durão AMS, Ramos APP, Crippa JA de S, Queiroz RHC. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up [Internet]. Therapeutic Advances in Psychopharmacology. 2014 ; 4( 1): 30-36.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1177/2045125313507738 - Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine
- Cannabidiol (CBD) for the treatment of bipolar affective disorder
- The therapeutic potential of harmine and ayahuasca in depression: evidence from exploratory animal and human studies
- Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
- Postural balance in patients with social anxiety disorder
- Short-term treatment of Catatonia with amantadine in schizophrenia and schizoaffective disorder. [Carta]
- New treatment options for panic disorder: clinical trials from 2000 to 2010
- Public speaking in social phobia: a pilot study of self-ratings and observers' ratings of social skills
- Arterial spin labeling in patients with schizophrenia: a systematic review
- Randomized, open naturalistic, acute treatment of panic Disorder with clonazepam or paroxetine [carta]
Informações sobre o DOI: 10.1177/2045125313507738 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
